Teva Blends Branded And Generic Mindsets To Boost Biosimilars
US Generics COO Says Teva Is ‘Uniquely Qualified’ To Succeed In The Biosimilar Arena
Executive Summary
Teva is “uniquely qualified” to succeed with biosimilars thanks to the dual branded and generic mindsets that it can bring to the table, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the second part of an exclusive interview.
You may also be interested in...
End Of Schultz Era Looms For Teva
Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.
Alvotech Could Upend Expectations For US Humira Biosimilars
In the second part of an exclusive two-part interview with Generics Bulletin, Alvotech founder and chairman Robert Wessman sets out the firm’s expectations for its rival to Humira, as Alvotech continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.
Generics Bulletin Editor’s Picks For Q4 2021
As 2021 drew to a close, there was no shortage of exciting developments for the off-patent industry. Alongside news of a strategic review affecting one of the biggest generics and biosimilars players, Generics Bulletin also held its annual Global Generics & Biosimilars Awards and brought readers fresh and exclusive insights from top industry executives.